RB

RegenX Biosciences

IPO

Improving lives through the curative potential of gene therapy

Rockville, United States · Founded 2008 · $108.4M raised

Employees
201–500
Founded
2008
Business Model
B2B
Total Funding
$108.4M
Last Round
$70.5M Series DMay 2015
Rounds
3

About

REGENXBIO is a leading clinical-stage biotechnology company developing gene therapy treatments using its proprietary NAV® Technology Platform, which encompasses over 100 novel AAV vectors. The company focuses on rare and retinal diseases including wet AMD, Duchenne muscular dystrophy, and MPS II, aiming to deliver one-time curative treatments to patients.

Summary

RegenX Biosciences is a Biotech company based in Rockville, United States, founded in 2008. It has raised $108.4M in total across 3 rounds, most recently a $70.5M Series D round in May 2015.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

IPOSep 2015

Sign up to see all 4 rounds

Seed through IPO — per-round amounts, valuations, and who invested in each round.

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

RegenX Biosciences on Indexed.vc
<a href="https://indexed.vc/companies/regenx-biosciences"><img src="https://indexed.vc/api/badge/company/regenx-biosciences" alt="RegenX Biosciences on Indexed.vc" width="260" height="76" /></a>